Cushman & Wakefield Reports Strong Revenue & Cash Flow Growth Despite $177M JV Impairment in 2025 Annual Results
Summary
Cushman & Wakefield reported a 9% revenue increase and 13% Adjusted EBITDA growth in 2025, alongside a 64% surge in operating cash flow, despite a $177.0 million non-cash impairment loss on a joint venture that impacted net income.
Key Events
-
Strong Revenue Growth
Total revenue increased 9% to $10.3 billion for the year ended December 31, 2025, driven by strong performance across all service lines, with Capital Markets revenue up 19% and Leasing revenue up 8%.
-
Net Income Impacted by Impairment
Net income decreased 33% to $88.2 million, and diluted EPS fell to $0.38, primarily due to a $177.0 million non-cash other-than-temporary impairment loss on the Greystone Joint Venture.
-
Robust Operational Profitability
Adjusted EBITDA increased 13% to $656.2 million, reflecting strong underlying operational performance before the non-cash impairment and other non-recurring items.
-
Significant Operating Cash Flow Improvement
Net cash provided by operating activities surged 64% to $340.4 million, demonstrating enhanced cash generation from core operations.
Analysis
Cushman & Wakefield's 2025 annual report presents a mixed financial performance, with strong operational growth and cash generation offset by a significant non-cash impairment. While net income and diluted EPS declined due to a $177.0 million impairment on the Greystone JV, the company achieved robust revenue growth across all segments and a substantial increase in Adjusted EBITDA. The improved operating cash flow and proactive debt management, including prepayments and a revolver extension, highlight underlying business strength and enhanced financial flexibility. Investors should consider the one-time nature of the impairment against the positive operational momentum and liquidity position.
At the time of this filing, CWK was trading at $13.13 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $3B. The 52-week trading range was $7.64 to $17.40. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.